EMA grants Rexgenero's Lead Product REX-001 Advanced Therapy Medicinal Product Certificate for Manufacturing Quality and Non-clinical Data

LONDON, January 30, 2018 /PRNewswire/ -- REX-001 is a novel cell therapy for the treatment of Critical Limb Ischemia (CLI), a disease which affects an estimated one million people in Europe Rexgenero Ltd, a clinical-stage regenerative medicine company developing advanced...

from PR Newswire: //http://ift.tt/2DKlFVK